Parotid Gland Removal — Cost, Top Hospitals & Success Rates | MyMedicPlus

The parotid gland is the largest of the three paired major salivary glands, located in front of and below each ear. It wraps around the mandibular ramus and is divided by the facial nerve into a superficial lobe (approximately 80% of glandular tissue) and a deep lobe. The parotid produces serous saliva rich in amylase, contributing around 25% of total daily salivary output.

Parotid gland removal — known medically as parotidectomy — is one of the most technically demanding operations in head and neck surgery because the facial nerve, which controls all movement of the face, courses directly through the gland. Surgeons must meticulously identify, dissect, and preserve the nerve while removing the diseased tissue.

Surgery is indicated for a range of conditions: benign tumours (which account for 75–80% of parotid neoplasms), malignant tumours, recurrent or uncontrolled infections, obstructing stones, and autoimmune conditions refractory to medical treatment. This guide explains what patients can expect from the process of having a parotid gland removed — from diagnosis and preparation through surgery, recovery, and long-term outcomes.

Surgical removal of the parotid gland is recommended for several distinct conditions:

• Pleomorphic adenoma (benign mixed tumour): The most common parotid tumour, accounting for 60–70% of cases. Despite being benign, it must be removed with a margin of normal tissue because simple enucleation leads to 20–40% recurrence. Malignant transformation to carcinoma ex-pleomorphic adenoma occurs in 6–10% of long-standing tumours.
• Warthin tumour (papillary cystadenoma lymphomatosum): The second most common benign tumour, seen predominantly in older male smokers. Bilateral in 10% of cases. Surgery is curative.
• Mucoepidermoid carcinoma: The most common primary parotid malignancy. Low-grade lesions are often cured by surgery alone; high-grade tumours require total parotidectomy, neck dissection, and adjuvant radiotherapy.
• Acinic cell carcinoma and adenoid cystic carcinoma: Less common malignancies requiring wide excision with particular attention to perineural spread.
• Chronic parotitis and sialolithiasis: Recurrent infections or stones not amenable to endoscopic sialendoscopy may require partial or total parotidectomy.
• Sjögren syndrome complications: Severe lymphoepithelial lesions or MALT lymphoma arising in Sjögren-affected parotid glands may require surgical management.

Patient selection is based on lesion pathology, lesion location and extent, patient fitness, and the likelihood that less invasive alternatives will succeed:

• Tumour diagnosis: Any solid parotid mass warrants evaluation. Fine-needle aspiration cytology (FNAC) provides pre-operative pathological guidance. MRI with contrast is the imaging modality of choice to delineate superficial versus deep lobe involvement and relationship to the facial nerve.
• Benign tumours: Surgery is recommended for most benign tumours given the risk of growth, malignant transformation (for pleomorphic adenoma), and diagnostic uncertainty on FNAC alone.
• Malignant tumours: Surgery is the cornerstone of treatment for all resectable parotid cancers. Resectability and operative extent are determined by tumour stage (TNM), nerve involvement, and extent of local invasion.
• Chronic disease: Patients with recurrent parotitis, multiple stones, or abscess formation unresponsive to antibiotics and sialendoscopy are offered parotidectomy.
• Fitness for general anaesthesia: Standard pre-operative cardiopulmonary assessment. Patients on anticoagulants require a bridging plan given the vascular nature of the dissection.

The extent of parotidectomy is tailored to the pathology and location of disease:

• Superficial parotidectomy: Removal of the superficial lobe only (approximately 80% of parotid tissue), with identification and preservation of the facial nerve. Appropriate for most benign tumours in the superficial lobe. The gold-standard approach for pleomorphic adenoma — provides adequate margin without the risk of deeper dissection.
• Total parotidectomy: Removal of both superficial and deep lobes while preserving the facial nerve. Required for deep lobe tumours, large benign lesions, and for most parotid malignancies. The facial nerve is at greater risk during deep lobe dissection.
• Radical (extended total) parotidectomy: Includes intentional sacrifice of the facial nerve when it is directly invaded by malignancy. Immediate nerve reconstruction (cable graft using sural nerve or great auricular nerve) is performed simultaneously to restore facial function over 6–12 months.
• Extracapsular dissection (ECD): A more limited technique for small, mobile, superficial benign tumours — the tumour is removed with a thin cuff of normal parotid tissue without formal identification of the main facial nerve trunk. Complication rates may be lower for small tumours, but recurrence data for pleomorphic adenoma are debated.
• Endoscopic-assisted and robot-assisted approaches: Emerging techniques using retroauricular or facelift incisions to eliminate visible scarring. Available at specialist centres.

Surgical removal offers outcomes unavailable through medical therapy for most parotid conditions:

• Definitive tumour control: Cure rates exceed 95% for benign tumours with adequate margins. For low-grade malignancies, surgery alone achieves local control in 80–90% of patients.
• Accurate histopathological diagnosis: Definitive tissue diagnosis, including grade and margin status for malignant lesions, guides adjuvant treatment decisions.
• Prevention of malignant transformation: Removing pleomorphic adenomas prevents the approximately 1% per-year risk of carcinoma ex-pleomorphic adenoma in long-standing lesions.
• Resolution of chronic symptoms: Patients with recurrent parotitis or obstructive disease experience complete resolution of episodic facial pain, swelling, and infection.
• Cosmetic improvement: Removal of visible parotid masses (which can become disfiguring) restores normal facial contour.

Patients must be counselled thoroughly about the risks specific to parotid surgery:

• Temporary facial nerve weakness: Occurs in 20–45% of patients after total parotidectomy and 10–20% after superficial parotidectomy due to nerve handling. Recovery is expected within 3–6 months in most cases. Intraoperative nerve monitoring (IONM) reduces permanent injury risk.
• Permanent facial nerve palsy: Rare in benign disease (<1%) when the nerve is structurally intact. In malignant disease requiring nerve sacrifice, immediate reconstruction is offered.
• Frey syndrome (gustatory sweating): Affects 30–50% of patients — flushing and sweating of the cheek and pre-auricular area when eating. Mild in most; Botox injection provides effective relief for symptomatic cases.
• Greater auricular nerve numbness: This sensory nerve is typically divided during exposure, causing numbness of the earlobe and lower ear. Partial recovery occurs in many patients over 12–18 months.
• Salivary fistula and sialocele: Fluid accumulation from residual parotid tissue in 5–10% of cases. Managed with pressure dressings, aspiration, and occasionally Botox injection to suppress salivary output.
• Wound complications: Haematoma, infection, and keloid formation are uncommon but documented risks. Drain removal on day 1–2 reduces haematoma risk.

Recovery from parotid gland removal follows a predictable course:

• Hospital stay (1–3 days): A drain is typically placed and removed when output falls below 20–30 mL per 24 hours. Oral diet begins day 1. Pain is managed with paracetamol and NSAIDs; opioids are rarely required.
• First 2 weeks: Facial swelling peaks at 48–72 hours and resolves progressively. Patients should keep the head elevated and avoid strenuous activity. Sutures or surgical clips are removed at 10–14 days. Mild mouth dryness is common initially.
• Weeks 2–6: Facial nerve function is assessed at each visit. Physiotherapy — gentle facial exercises — is initiated early if any weakness is present to prevent synkinesis. Wound massage with moisturiser can optimise scar outcome.
• 3–6 months: Histopathology review confirms margins and grade. For malignant tumours, adjuvant radiotherapy typically begins 4–6 weeks post-operatively. PET-CT or MRI at 3–6 months for surveillance of high-grade cancers.
• Long-term: Annual follow-up for 5 years (benign) or 10 years (malignant). Pleomorphic adenoma patients warrant imaging at 1 and 5 years given the rare risk of recurrence even with adequate margins.

Parotidectomy costs depend on operative extent, hospital setting, nerve monitoring use, and country. Representative ranges:

• United States: USD 20,000–45,000 (all-inclusive, inpatient)
• United Kingdom (private): GBP 10,000–18,000
• India (JCI/NABH-accredited): USD 3,500–8,000
• Thailand: USD 5,000–10,000
• Turkey: USD 4,000–9,000
• Singapore: USD 8,000–15,000

Additional cost drivers include intraoperative facial nerve monitoring equipment, frozen section pathology, neck dissection (if malignant), nerve grafting (sural or great auricular), and post-operative radiotherapy. Medical tourists should plan for 7–10 days in-country (longer for malignant cases requiring post-operative oncology review). Always verify surgeon head-and-neck credentials and hospital accreditation.

Not all parotid conditions require gland removal. The following alternatives are appropriate in selected cases:

• Sialendoscopy: Minimally invasive endoscopic technique for removing parotid duct stones (sialolithiasis) and dilating strictures. Highly effective for obstructive disease; avoids open surgery entirely in many patients.
• Extracorporeal shock wave lithotripsy (ESWL): Fragmentation of parotid duct stones using focused shock waves, followed by endoscopic clearance. Suitable for stones in the distal duct that cannot be retrieved endoscopically.
• Botulinum toxin (Botox) injection: Reduces salivary secretion in recurrent parotitis, Frey syndrome, and sialoceles. Requires repeated treatments every 4–6 months but avoids surgery.
• Antibiotics and conservative management: Acute bacterial parotitis is treated medically. Chronic conditions are managed with sialogogues, oral hygiene, hydration, and massage before surgery is considered.
• Observation (watchful waiting): Small, stable, likely benign lesions (especially in elderly or frail patients) may be monitored with periodic MRI if FNAC is reassuring and the lesion is not enlarging. Not appropriate for lesions showing growth or cytological atypia.